Quick search:
Content Search
Result Content Research
Result Content Research
1 Mesoblast's Novartis-partnered COVID-19 cell therapy hits a wall as FDA requests new trial
2 Mesoblast (MESO) falls 4.86% to Close at $5.87 on September 20
3 Mesoblast Corporate Update and Financial Results Webcast
4 Mesoblast reveals more COVID trials needed, shares tumble
5 Mesoblast shares dive 16pc as FDA raises more questions
6 Auditors Are Concerned About Mesoblast (ASX:MSB)
7 2021 Pipeline Insight Report on Myocardial Infarction
8 Is Mesoblast limited (MESO) Stock Worth a Buy Wednesday?
9 Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions
10 Loss-Making Mesoblast Limited (ASX:MSB) Expected To Breakeven In The Medium-Term
11 Mesoblast (MESO) falls 2.84% in Light Trading on September 17
12 Mesoblast (MESO) falls 0.78% on Moderate Volume September 14
13 Top broker tips Mesoblast (ASX:MSB) share price to double in value
14 Global Rheumatoid Arthritis Stem Cell Therapy Market 2021 Data Analysis by Key vendors like Mesoblast, Roslin Cells, Regeneus, ReNeuron Group – Bulk Solids Handling
15 Covid-19 roundup: Pfizer, Merck start late-stage trials for Covid-19 pills; Merck begins PhIII study on post-exposure treatment
16 Mesoblast (MESO) gains 0.68% in Active Trading on August 27
17 ASX 200 rises, Harvey Norman falls, Mesoblast sinks
18 Why Bubs, Harvey Norman, Mesoblast, & Regis shares are dropping
19 As it happened: ASX gains 0.4% as healthcare, industrials and IT lead
20 Stem Cell Reconstructive Market Growth, Developments Analysis and Precise Outlook 2021 to 2028 Baxter, Cytori Therapeutics Inc., Eleveflow, Mesoblast Ltd. – Stillwater Current
21 The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
22 Mesoblast Earnings, Revenue miss in Q4 By
23 Mesoblast Provides Update on Program for Chronic Low Back Pain Due to Degenerative Disc Disease
24 Could new findings put Mesoblast back in the COVID treatment race?
25 Mesoblast reports 90-day enhanced survival outcomes for remestemcel-L
26 Mesoblast Completes US$110/A$138 Million Financing Led by US Strategic Investor Group
27 Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
28 North America Tissue Regenaration Market 2021 Industry Trends, Segments, Opportunities and Growth Forecast 2028 – Stillwater Current
29 These 3 ASX 200 shares are the most traded this Tuesday
30 Mesoblast Operational Highlights and Upcoming Milestones
31 Mesoblast craters as Novartis-backed COVID-19 drug flunks trial
32 Mesoblast Phase 3 Trial Shows That a Single Injection of
33 After Mesoblast COVID-19 drug flop, Novartis tries again with Molecular Partners
34 Allogeneic Stem Cells Market 2021 Overview with Demographic Data and Industry Growth Trends 2028 – Stillwater Current
35 Mesoblast Presents Respiratory Function Results of COVID-19
36 ‘There’s always a way forward’: Crunchtime for Mesoblast as legal threats loom
37 Appendix 4C Quarterly Activity Report
38 Advanced Human Imaging (ASX:AHI) plans to reap rewards of a NASDAQ listing
39 Mesoblast Updates On Rexlemestrocel-L Program In Chronic Low Back Pain
40 Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data
41 Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group
42 Mesoblast slumps to $US29.15m loss after FDA false start
43 Mesoblast outlines results from trial of remestemcel-L in COVID-19
44 Mesoblast's stem cell therapy fails to meet primary endpoint in COVID-19 study
45 Novartis licenses phase 3 COVID-19 cell therapy from Mesoblast
46 SurgCenter Development principals invest in Mesoblast, exec joins board
47 Mesoblast talks Ryoncil, COVID-19 and manufacturing
48 Mesoblast's Revascor fails to meet primary endpoint in phase III chronic heart failure trial
49 Mesoblast Provides Topline Results From Phase 3 Trial of
50 These are the 10 most shorted ASX shares 20 September 2021
51 Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
52 Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference
53 Ownership Matters tallies up Mesoblast cash outflows, raises
54 Investors in drugmaker Mesoblast sweat on crucial capital raising
55 Global Mesenchymal Stem Cells Market Report 2021 Market SWOT Analysis, Key Indicators, Forecast 2028 – Stillwater Current
56 The Pharma Letter Podcast — Episode 2 — Non-opioid analgesics
57 Mesoblast: The Future Looks Bleak
58 Mesoblast Receives Complete Response Letter From the FDA
59 Mesoblast can't catch a break | Evaluate
60 Mesoblast readies $100m private placement
61 Pharmaceutical Company, Investment Bank Take Space at 505 Fifth Avenue – Commercial Observer
62 Mesoblast Limited: Is Stemcell Therapy Ready For Prime Time?
63 Stem Cell Therapy Market the Next Big Thing, Major Giants
64 Mesoblast's Time May Be Up
65 Mesoblast's selective disclosure continues
66 Philip J. Facchina, Chief Strategy Officer and Principal of SurgCenter...
67 Mesoblast (ASX:MSB) flags upcoming major private placement
68 Analysts Are More Bearish On Mesoblast Limited (ASX:MSB) Than They Used To Be
69 Mesoblast phase III chronic back pain trial meets pain reduction endpoint, reduces opioid use
70 Mesoblast’s friends maintain the faith
71 Shock as FDA rejects Mesoblast's Ryoncil in paediatric graft versus host disease
72 Investors Who Bought Mesoblast (ASX:MSB) Shares Five Years Ago Are Now Up 76%
73 FDA Action Alert: Aquestive, Eton and Mesoblast
74 Beach Energy drags Australia shares lower, Mesoblast limits losses
75 Mesoblast Stock Soars on Promise of Cellular Medicine
76 Mesoblast (MESO) Q1 2021 Earnings Call Transcript
77 Tissue Regeneration Market Size, Share and Top Vendors – Arteriocyte Medical Systems Inc., Cerapedics Inc., Athersys Inc., Co. Don AG, Cook Medical Inc., Cryolife Inc., Cytori Therapeutics Inc. – Stillwater Current
78 Where Do Hedge Funds Stand On Mesoblast Limited (MESO)?
79 These are the 10 most shorted ASX shares 13 September 2021
80 Tissue Regeneration Market Analysis and Forecast 2021 | Athersys Inc., Cerapedics Inc., CryoLife, Inc., Cytori
81 COVID-19 cell therapy drives Mesoblast to seek manufacturing muscle
82 Why does the Mesoblast (ASX:MSB) share price keep falling?
83 Novartis Puts Down $50m For Mesoblast COVID-19 Cell Therapy
84 Why the Mesoblast (ASX:MSB) share price is edging higher on Tuesday
85 The Mesoblast (ASX:MSB) share price has rocketed 18% this week
86 Here are the top ASX large cap movers for Tuesday
87 Stem cell therapy could make significant impact as opioid alternative
88 Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHDQuarterly Activity Report
89 FDA Grants Fast Track Designation for Remestemcel-L in the
90 Mesoblast Needs A Solution To MSC Scalability Issues
91 Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-L
92 Mesoblast Reports Substantial Operational Progress and Financial Results for the Year Ended June 30, 2020
93 Why Cynata is hopeful its COVID treatment trial will succeed where others have failed
94 Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
95 54 Biggest Movers From Yesterday
96 InvestorChannel’s Covid-19 Watchlist Update for Monday, September, 20, 2021, 16:00 EST
97 What Kind Of Shareholders Hold The Majority In Mesoblast Limited's (ASX:MSB) Shares?
98 AdComm backs Mesoblast cell therapy despite manufacturing concerns
99 Promising Results for Stem Cell Treatment of Degenerative Disc Disease
100 ASX Update: Miners lead rebound as US futures rise